Predominantly Persistent Intraretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments Trials

Keyphrases

• Age-related Macular Degeneration 100%
• Treatment Trials 100%
• Subretinal Fluid 100%
• Visual Acuity 61%
• Acuity Score 33%
• Scar 16%
• Pro Re Nata 11%
• Anatomic 5%
• Bevacizumab 5%
• Linear Regression Analysis 5%
• Randomized Clinical Trial 5%
• Reading Center 5%
• Adjusted Hazard Ratio 5%
• Ranibizumab 5%
• Neovascular Age-related Macular Degeneration (nAMD) 5%
• Adjusted Means 5%
• Baseline Predictors 5%
• Patient Features 5%
• Visual Acuity Change 5%
• Persistent Subretinal Fluid 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Age Related Macular Degeneration 100%
• Randomized Clinical Trial 50%
• Bevacizumab 50%
• Ranibizumab 50%
• Wet Macular Degeneration 50%
• Subretinal Fluid 50%

Medicine and Dentistry

• Age Related Macular Degeneration 100%
• Visual Acuity 100%
• Optical Coherence Tomography 16%
• Hazard Ratio 8%
• Bevacizumab 8%
• Linear Regression Analysis 8%
• Ranibizumab 8%
• Wet Macular Degeneration 8%
• Subretinal Fluid 8%
• Randomized Clinical Trials 8%